EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial

Stewart J Tepper, Liron Rabany, Robert P Cowan, Timothy R Smith, Brian M Grosberg, Bradley D Torphy, Dagan Harris, Maya Vizel, Alon Ironi, Alit Stark-Inbar, Andrew M Blumenfeld

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14469 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, 2023. Verfasst von Stewart J Tepper und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Theranica Bio-Electronics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the clinical efficacy of remote electrical neuromodulation (REN), used every other day, for the prevention of migraine.

Background

Preventive treatment is key to managing migraine, but it is often underutilized. REN, a non‐pharmacological acute treatment for migraine, was evaluated as a method of migraine prevention in patients with episodic and chronic migraine.

Methods

We conducted a prospective, randomized, double‐blind, placebo‐controlled, multi‐center trial, with 1:1 ratio. The study consisted of a 4‐week baseline observation phase, and an 8‐week double‐blind intervention phase in which participants used either REN or a placebo stimulation every other day. Throughout the study, participants reported their symptoms daily, via an electronic diary.

Results

Two hundred forty‐eight participants were randomized (128 active, 120 placebo), of which 179 qualified for the modified intention‐to‐treat (mITT) analysis (95 active; 84 placebo). REN was superior to placebo in the primary endpoint, change in mean number of migraine days per month from baseline, with mean reduction of 4.0 ± SD of 4.0 days (1.3 ± 4.0 in placebo, therapeutic gain = 2.7 [confidence interval −3.9 to −1.5], p < 0.001). The significance was maintained when analyzing the episodic (−3.2 ± 3.4 vs. −1.0 ± 3.6, p = 0.003) and chronic (−4.7 ± 4.4 vs. −1.6 ± 4.4, p = 0.001) migraine subgroups separately. REN was also superior to placebo in reduction of moderate/severe headache days (3.8 ± 3.9 vs. 2.2 ± 3.6, p = 0.005), reduction of headache days of all severities (4.5 ± 4.1 vs. 1.8 ± 4.6, p < 0.001), percentage of patients achieving 50% reduction in moderate/severe headache days (51.6% [49/95] vs. 35.7% [30/84], p = 0.033), and reduction in days of acute medication intake (3.5 ± 4.1 vs. 1.4 ± 4.3, p = 0.001). Similar results were obtained in the ITT analysis. No serious device‐related adverse events were reported in any group.

Conclusion

Applied every other day, REN is effective and safe for the prevention of migraine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersHumansProspective StudiesTreatment OutcomeHeadacheDouble-Blind Method

Stichwörter der Autor:innen

headachemigraineneuromodulationnon-pharmacologicalpreventionprophylaxis

Autor:innen und Institutionen

  • The Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Theranica Bio-Electronics Ltd., Netanya, Israel.
  • Division of Headache Medicine, Stanford University, Palo Alto, California, USA.
  • StudyMetrix Research, St. Peters, Missouri, USA.
  • Hartford Healthcare Headache Center, Hartford, Connecticut, USA.
  • Chicago Headache Center and Research Institute, Chicago, Illinois, USA.

Förderung

  • Theranica Bio-Electronics

Zitieren

APA

Tepper, S. J., Rabany, L., Cowan, R. P., Smith, T. R., Grosberg, B. M., Torphy, B. D., Harris, D., Vizel, M., Ironi, A., Stark-Inbar, A., & Blumenfeld, A. M. (2023). Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14469

Vancouver

Tepper SJ, Rabany L, Cowan RP, Smith TR, Grosberg BM, Torphy BD, et al. Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14469

BibTeX
@article{Tepper2023,
  author = {Tepper, Stewart J and Rabany, Liron and Cowan, Robert P and Smith, Timothy R and Grosberg, Brian M and Torphy, Bradley D and Harris, Dagan and Vizel, Maya and Ironi, Alon and Stark-Inbar, Alit and Blumenfeld, Andrew M},
  title = {Remote electrical neuromodulation for migraine prevention: A double‐blind, randomized, placebo‐controlled clinical trial},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14469}
}
Kostenlos starten →